Publication:
Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status

dc.contributor.authorAmar Nagilaen_US
dc.contributor.authorThinnakorn Permpongpaiboonen_US
dc.contributor.authorSoontharee Tantrarongrojen_US
dc.contributor.authorPornwalee Porapakkhamen_US
dc.contributor.authorKultira Chinwattanaen_US
dc.contributor.authorSara Deakinen_US
dc.contributor.authorSureerut Porntadavityen_US
dc.contributor.otherFishtail Hospitalen_US
dc.contributor.otherHuachiew Chalermprakiat Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherHopitaux universitaires de Geneveen_US
dc.date.accessioned2018-09-13T07:13:43Z
dc.date.available2018-09-13T07:13:43Z
dc.date.issued2009-01-01en_US
dc.description.abstractIt has been proposed that paraoxonasel (PON1), a high density lipoprotein (HDL)-associated esterase/lactonase, has antiatherosclerotic properties. The activity of PON1 is influenced by PON1 polymorphisms. However, the influence of PON1 polymorphisms on PON1 activity and oxidative stress in response to lipid-lowering drugs remains poorly understood. The objective of the present study was to investigate the effects of atorvastatin on PON1 activity and oxidative status. The influence of PON1 polymorphisms on PON1 activity and oxidative status in response to atorvastatin treatment was also evaluated. In total, 22 hypercholesterolemic patients were treated with atorvastatin at a dose of 10 mg/day for 3 months. Lipid profile, lipid oxidation markers (malondialdehyde (MDA), conjugated diene (CD), total peroxides (TP)), total antioxidant substance (TAS), oxidative stress index (OSI), and paraoxonasel activity were determined before and after treatment. L55M, Q192R, and T(-107)C PON1 polymorphisms were also determined. Atorvastatin treatment significantly reduced the levels of total cholesterol (24.5%), low density lipoprotein (LDL) cholesterol (25.4%), triglycerides (24.4%), CD (4.4%), MDA (15.2%), TP (13.0%) and OSI (24.0%), and significantly increased the levels of TAS (27.3%), and PON1 activity (14.0%). Interestingly, the increase in PON1 activity and the reduction in oxidative stress in response to atorvastatin were influenced only by the PON1 T-107C polymorphism. Atorvastatin treatment improved the lipid profile, lipid oxidation, and oxidative/antioxidative status markers including the activity of PON1 towards paraoxon. These beneficial effects may be attributed to the antioxidant properties of statins and the increase in PON1 activity. The increase in PON1 activity was enhanced by the PON1 T-107C polymorphism. Copyright © 2009 by Institute of Pharmacology Polish Academy of Sciences.en_US
dc.identifier.citationPharmacological Reports. Vol.61, No.5 (2009), 892-898en_US
dc.identifier.doi10.1016/S1734-1140(09)70146-Xen_US
dc.identifier.issn17341140en_US
dc.identifier.other2-s2.0-70549110067en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/28335
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=70549110067&origin=inwarden_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleEffect of atorvastatin on paraoxonase1 (PON1) and oxidative statusen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=70549110067&origin=inwarden_US

Files

Collections